Sergey Vlasenko’s Post

In case you missed it: in this Pharma's Almanac roundtable, a panel of industry experts weighs in on the most significant regulatory decision or guidance influencing biopharma in 2024 and beyond. Read the roundtable here: https://lnkd.in/g-yU58uV Our roundtable includes contributors from GBI Bio, Lonza, MilliporeSigma, PPD, Samsung Biologics, Tedor Pharma Services, ADVI Health, Agilent Technologies, Astrea Bioseparations, Atomic AI, BioBridge Global, BioIVT, BIOSENIC S.A., Bruker BioSpin, Cellares, Cyclacel Limited, eClinical Solutions, Ellab - Validation & Monitoring Solutions, Evonik, Faeth Therapeutics, HDT Bio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, OM1, Inc., OrganaBio, Organon, Ori Biotech, OzUK, Pharmatech Associates, a USP company, PointClickCare, ScaleReady, SCIEX, SCTbio, Sernova, ...(cont) #Regulatory #Biopharma #Roundtable

Thoughts on this? >> Lyell Immunopharma to acquire ImmPACT Bio, cut top programs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

Introducing analytical methods in drug discovery takes time - learn how scientists from Novartis, Biogen and SCIEX screen and analyze intact proteins in discovery assays in this roundtable. Watch here: https://bit.ly/3Wmy23O #DanaherLifeSciences #Echo #MS #massspec #drugdiscovery

There are more than 300 GLP-1RAs in an active stage of development, from industry giants and potential market disrupters. While mega-cap companies dominate the GLP-1RA market and are expected to maintain their stronghold in 2030, three smaller biotechs – Viking Therapeutics, Inc., Altimmune, Inc., and Structure Therapeutics – are emerging as potential disrupters in this drug category, giving hope to innovative newcomers. Click here for the full article - https://lnkd.in/d8QNQ6z7 #pharma #GLP1 #biotech #biopharma

AsymBio will be on site in Biotech Showcase, which is the epicenter of the life science ecosystem, to demonstrate leading ADC CDMO solutions. From groundbreaking breakthroughs to strategic partnerships, it’s all happening here. #ADC #JPM #BiotechShowcase #biopharma #pharma #biopartnering

Suven Pharma’s Strategic Leap into the Future! Suven Pharmaceuticals has acquired a 56% stake in U.S.-based NJ Bio Inc., a specialized ADC-focused CRDMO, for ~$100 million. Why This Move Matters: 🔹 End-to-End ADC Capabilities: NJ Bio’s bioconjugation and linker technologies perfectly complement Suven’s expertise in payload chemistry and GMP manufacturing—offering seamless solutions for ADC development. 🔹 Expanding Modalities: Beyond ADCs, NJ Bio brings expertise in radioconjugates, oligonucleotide conjugation, and mRNA technologies—addressing next-gen therapeutic needs. 🔹 Global Growth: A stronger foothold in the U.S. market and access to 150+ global customers accelerates Suven’s journey as a global, technology-driven CDMO. The Bigger Picture: With increasing demand for targeted therapies, this strategic acquisition positions Suven to lead in innovation, speed, and scalability—creating value for pharma innovators, investors, and the biopharma ecosystem. Suven Pharma is now primed to shape the future of precision therapeutics. 🌍 #pharma #biopharma #strategy #biotech #business

Denmark-based Adcendo is the latest biotech to secure funding in the antibody-drug conjugate (ADC) space, raising $135m to advance its portfolio of first-in-class ADCs into the clinic.  Click here for the full article - https://lnkd.in/dsP86sxR #pharma #ADCs #biotech #biopharma

Dive into Pharma's Almanac roundtable for insights from leading experts at companies like Lonza, Samsung Biologics, and Thermo Fisher Scientific. Discover how the pharmaceutical industry is harnessing fresh ideas from adjacent sectors to boost drug development! 

The Final Competition of Epoch IV Though it’s the last, it’s certainly not the least. This competition, hosted by Leash Bio, aims to predict small molecule-protein interactions, a crucial aspect of drug development. Machine learning (ML) models can predict the binding affinity of small molecules to specific protein targets- a critical step in drug development for the pharmaceutical industry that paves the way for more accurate drug discovery. This competition links to goal #3: Good health and well-being. Using machine learning to search for the perfect ligand in the 1060 chemicals in the drug-like space will revolutionize the way medicine is developed and could speed up the process of curing diseases.